BioMarin Pharmaceutical Inc
BioMarin Pharmaceutical Inc/ US09061G1013 /
BMRN
|
2024-04-18 10:00:00 PM
|
Chg.
-0.4000
|
Volume |
Bid11:44:39 PM |
Ask11:44:39 PM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
90.0700USD
|
-0.44%
|
944,850
Turnover: 60.15 mill. |
82.0000Bid Size: 500 |
92.8800Ask Size: 100 |
16.99 bill.USD |
- |
101.20 |
Business description
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates.
Management board & Supervisory board
| CEO |
| Jean-Jacques Bienaimé |
| Management board |
| Brian Mueller, Amy Wireman, Dr. Brinda Balakrishnan, Dr. C. Greg Guyer, G. Eric Davis, Henry J. Fuchs, Jeff Ajer, Philip Lo Scalzo |
| Supervisory board |
| Jean-Jacques Bienaimé, David Pyott, Dr. Dennis J. Slamon, Dr. Elaine J. Heron, Dr. V. Bryan Lawlis, Elizabeth Anderson, Mark Alles, Maykin Ho, Richard A. Meier, Robert Hombach, Willard H. Dere |
Company data
| Name: |
Biomarin Pharmaceutical Inc. |
| Address: |
770 Lindaro Street,San Rafael, California 94901, USA |
| Phone: |
+1-415-506-6700 |
| Fax: |
+1-415-3827889 |
| E-mail: |
-
|
| Internet: |
www.bmrn.com/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
12-31 |
| Free Float: |
58.89% |
| IPO date: |
1999-07-01 |
Investor relations
| Name: |
Traci McCarty |
| IR phone: |
+1-415-455-7558 |
| IR Fax: |
- |
| IR e-mail: |
IR@BMRN.com
|
Main Shareholders
| Freefloat |
|
58.89% |
| PRIMECAP Management Company |
|
9.67% |
| The Vanguard Group |
|
8.88% |
| Dodge & Cox |
|
8.05% |
| BlackRock, Inc. |
|
7.62% |
| Capital Research Global Investors |
|
6.89% |
